-
Merck global boss substitution!
Time of Update: 2022-10-31
" ” Frazier said: "On behalf of Merck management and our colleagues around the world, I would like to express our deepest gratitude to Ken for his countless contributions and indelible impact on our company and global health," Davis said.
-
Health care negotiations are coming! Analysis of the competitive landscape of 343 varieties
Time of Update: 2022-10-31
Recently, the National Medical Insurance Administration issued the "Announcement on the Phased Results of Expert Review of Declared Drugs Approved by the Formal Review of the National Medical Insuran
-
Baekje PD-1 transferred to Europe, who can Junshi and Akeso win the FDA's first indication for nasopharyngeal carcinoma? Why has Europe become a "real fragrant" place to go to sea?
Time of Update: 2022-10-31
gov), the three domestic pharmaceutical companies that have planned to market the indications for PD-1 nasopharyngeal carcinoma in the United States - BeiGene, Junshi Biologics and Akeso Biologics are based on almost all clinical trials that lack European and American data.
-
Half for and half against! GSK "Dapstal" has a difficult road to listing in the United States
Time of Update: 2022-10-31
On October 26, the FDA held an advisory committee meeting on Daprodustat, GSK's oral chronic kidney disease anemia (CKD) drug, and the mixed vote was mixed, half for and half against.
-
This week, a number of domestic new drug clinical trial applications were approved by the FDA!
Time of Update: 2022-10-31
Conclusion In general, with the high enthusiasm for domestic new drug research and development, the continuous increase in R&D investment of pharmaceutical companies, and the acceleration of new drug review and approval, a large number of domestic new drugs will enter the clinical trial stage in the future and accelerate their listing.
-
ADC pharmaceutical companies do not want to "hide into the dust", they must do a good job in the "life event" of project establishment!
Time of Update: 2022-10-31
Conclusion Conclusion For pharmaceutical companies, especially for Chinese pharmaceutical companies that are currently in a pile of targets, serious involution and fierce competition, ADC is indeed a rare golden track for new drug research and development based on the characteristics of multiple cancers, multiple organs and multiple targets.
-
The cold is transmitted to the ADC, and the popular varieties under research are "sold at a low price"
Time of Update: 2022-10-31
A domestic innovative pharmaceutical company also introduced this drug In July this year, Zhejiang Pharmaceutical, which is mainly engaged in APIs and intermediates, issued an announcement that its subsidiary Xinma Biotech completed the B round of financing, and after this financing, the valuation of Xinma Biotech reached more than 3 billion yuan.
-
Novartis antiepileptic drugs under supply pressure? MNC brand drug "Red Sea" is facing a breakthrough!
Time of Update: 2022-10-31
6 billion antiepileptic drugs market The share left for Qu Lai is getting smaller and smaller The share left for Qu Lai is getting smaller and smaller Developed by Novartis, oxcarbazepine was approved by the US FDA in 2000 and entered the Chinese market in 2004 under the trade name "Qulai".
-
The role of insurance in drug coverage
Time of Update: 2022-10-31
In the above context, many companies in the market are thinking about health insurance as a commercial payer, and high-cost items, especially expensive special drugs, new self-funded surgical projects, what kind of relationship, how to protect expensive medical projects, not only to obtain the value of protection, but also to obtain growth opportunities in the overall stall of health insurance in the Chinese market, which has become the thinking of all walks of life in the market.
-
5 billion! To create another "Tigermed Pharmaceutical", where is the confidence of Remegen?
Time of Update: 2022-10-31
In terms of commodity sales, Remegen has two products, tetacept (RC18) and vedicitumab (RC48), which have been approved for marketing, and achieved revenue of 131 million yuan through the sale of goods in 2021, accounting for 9.
-
The implementation of China's conditional approval procedures for drugs and related considerations
Time of Update: 2022-10-31
source source China Pharmaceutical Affairs, Vol. 36, No. 10, October 2022 author author YUAN Lijia,CHEN Xiaoming,ZHANG Ning Center for Drug Evaluation of the State Medical Products Administration sum
-
The growth rate of PD-1 "pin crown" slowed down, and Hengrui "Carellizhu" found a way out
Time of Update: 2022-10-31
IncyteCrystalGenomics (CG) breast cancer, cervical cancer, solid tumors Subsequent major clinical development pipeline of carrelizumab Screenshot source: corporate financial report Recently, Hengrui's innovative drug carrelizumab combined with familtinib first-line treatment of tumor cells PD-L1 expression positive [tumor proportion score (TPS) ≥1%] and not accompanied by EGFR/ALK gene abnormalities of recurrent or metastatic non-small cell lung cancer was proposed to be included in the list of breakthrough therapy varieties by the Center for Drug Evaluation of the National Medical Products Administration.
-
The instrument CDMO on the eve of the outbreak, the promised land of the next 10 times long cattle
Time of Update: 2022-10-31
According to the prospectus of Kaishi Biologics, the CDMO model of domestic diagnostic instruments started late, after 2000, the domestic began to gradually carry out professional division of labor, the number of enterprises with multi-platform research and development capabilities and large-scale production capacity is limited, different enterprises have their own characteristics and advantages in the subdivision of application fields, and the industry competition intensity is lower than that of the downstream diagnostic reagent industry.
-
Drug Discovery 12 new drugs approved by the FDA in the third quarter of 2022
Time of Update: 2022-10-31
Olipudase alfa (Xenpozyme; Sanofi) On August 30, the FDA approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of adult and pediatric patients with non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD), the first therapy specifically designed to treat ASMD and the only currently approved therapy for the disease.
-
The 1.5 billion yuan drug market is fiercely competitive, and a large number of pharmaceutical companies have been evaluated recently
Time of Update: 2022-10-31
For example, in early October, the website of the State Food and Drug Administration showed that Jiangsu Zhengda Qingjiang Pharmaceutical's cefixime tablets were approved for supplementary application, becoming the fourth enterprise to pass the evaluation of the product, and then the company's ellamod tablets were accepted by CDE for imitation of Class 4 applications.
-
Asia's first man! Wang Yongjun, president of Tiantan Hospital, won the world's highest achievement award in the field of stroke
Time of Update: 2022-10-31
Mark Fisher, president of the World Stroke Organization, said in his award speech that Wang Yongjun and his team have made many outstanding contributions in reducing the risk of residual recurrence of ischemic cerebrovascular disease.
-
Roche "denounces" stone medicine behind: a battle of interests under drug patents
Time of Update: 2022-10-31
On October 18, Roche Pharmaceuticals announced on its official WeChat public account that its innovative drug mabaloxavir tablets (trade name: Sofuda ®) was approved for marketing in China in April 2021, and the drugs and active ingredients are protected by relevant Chinese invention patents.
-
Global mAb market is nearly $500 billion by 2030, with a CAGR of 11.30%
Time of Update: 2022-10-31
Asia Pacific is expected to have the highest growth rate during the forecast period due to the large number of cancer treatment patients in the region and the expanding clinical research prospects of monoclonal antibodies.
-
The United States sold 570 million in half a year! Biotechs, who are not yet cold, wrap new clothes for cell therapy faucets
Time of Update: 2022-10-25
The cell therapy industry has been buzzing with good news lately. On October 19, GenScript Biologics announced that the BCMA CAR-T of its subsidiary Legend Biologics achieved net sales of 55 million
-
How do companies choose CMO?
Time of Update: 2022-10-25
The global market for contract processing outsourcing is growing, with more and more scientific institutions, pharmaceutical companies and biopharmaceutical companies choosing to outsource production to CMOs and drug development and manufacturing outsourcing services (CDMOs).
